Paul Tudor Jones's ABBV Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 113,543 shares of AbbVie Inc. (ABBV) worth $25.94 M, representing 0.05% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 44 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in ABBV, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2025, adding 330,873 shares. Largest reduction occurred in Q3 2025, reducing 330,873 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's AbbVie (ABBV) Holding Value Over Time
Track share changes against reported price movement
Quarterly AbbVie (ABBV) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +113,543 | New Buy | 113,543 | $228.49 |
| Q3 2025 | -330,873 | Sold Out | 0 | $0.00 |
| Q2 2025 | +330,873 | New Buy | 330,873 | $185.62 |
| Q1 2024 | -62,397 | Sold Out | 0 | $0.00 |
| Q4 2023 | +49,699 | Add 391.39% | 62,397 | $154.97 |
| Q3 2023 | -144,587 | Reduce 91.93% | 12,698 | $149.06 |
| Q2 2023 | +157,285 | New Buy | 157,285 | $134.73 |
| Q4 2022 | -10,591 | Sold Out | 0 | $0.00 |
| Q3 2022 | +2,124 | Add 25.09% | 10,591 | $134.17 |
| Q2 2022 | +8,467 | New Buy | 8,467 | $153.18 |
| Q1 2022 | -39,268 | Sold Out | 0 | $0.00 |
| Q4 2021 | +23,690 | Add 152.07% | 39,268 | $135.40 |
| Q3 2021 | -20,146 | Reduce 56.39% | 15,578 | $107.84 |
| Q2 2021 | +18,770 | Add 110.71% | 35,724 | $112.64 |
| Q1 2021 | +16,954 | New Buy | 16,954 | $108.23 |
| Q4 2020 | -48,175 | Sold Out | 0 | $0.00 |
| Q3 2020 | +48,175 | New Buy | 48,175 | $87.60 |
| Q2 2020 | -40,340 | Sold Out | 0 | $0.00 |
| Q1 2020 | -6,977 | Reduce 14.75% | 40,340 | $76.20 |
| Q4 2019 | +47,317 | New Buy | 47,317 | $88.53 |
| Q2 2019 | -38,614 | Sold Out | 0 | $0.00 |
| Q1 2019 | +38,614 | New Buy | 38,614 | $80.59 |
| Q4 2018 | -125,972 | Sold Out | 0 | $0.00 |
| Q3 2018 | -23,195 | Reduce 15.55% | 125,972 | $94.58 |
| Q2 2018 | +63,113 | Add 73.34% | 149,167 | $92.65 |
| Q1 2018 | +86,054 | New Buy | 86,054 | $94.65 |
| Q3 2017 | -15,220 | Sold Out | 0 | $0.00 |
| Q2 2017 | +3,058 | Add 25.14% | 15,220 | $72.54 |
| Q1 2017 | +7,262 | Add 148.20% | 12,162 | $65.12 |
| Q4 2016 | -4,000 | Reduce 44.94% | 4,900 | $62.65 |
| Q3 2016 | +8,900 | New Buy | 8,900 | $63.03 |
| Q2 2016 | -4,100 | Sold Out | 0 | $0.00 |
| Q1 2016 | -28,825 | Reduce 87.55% | 4,100 | $57.07 |
| Q4 2015 | -16,555 | Reduce 33.46% | 32,925 | $59.23 |
| Q3 2015 | +42,980 | Add 661.23% | 49,480 | $54.41 |
| Q2 2015 | -3,570 | Reduce 35.45% | 6,500 | $67.23 |
| Q1 2015 | -2,844 | Reduce 22.02% | 10,070 | $58.49 |
| Q4 2014 | -248,786 | Reduce 95.07% | 12,914 | $65.43 |
| Q3 2014 | +4,356 | Add 1.69% | 261,700 | $57.76 |
| Q2 2014 | +257,344 | New Buy | 257,344 | $56.44 |
| Q1 2014 | -76,100 | Sold Out | 0 | $0.00 |
| Q4 2013 | -277,000 | Reduce 78.45% | 76,100 | $52.81 |
| Q3 2013 | +3,100 | Add 0.89% | 353,100 | $44.73 |
| Q2 2013 | +350,001 | Add 0.00% | 350,000 | $41.34 |
Paul Tudor Jones's AbbVie Investment FAQs
Paul Tudor Jones first purchased AbbVie Inc. (ABBV) in Q2 2013, acquiring 350,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held AbbVie Inc. (ABBV) for 44 quarters since Q2 2013.
Paul Tudor Jones's largest addition to AbbVie Inc. (ABBV) was in Q2 2013, adding 350,000 shares worth $14.47 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 113,543 shares of AbbVie Inc. (ABBV), valued at approximately $25.94 M.
As of the Q4 2025 filing, AbbVie Inc. (ABBV) represents approximately 0.05% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in AbbVie Inc. (ABBV) was 353,100 shares, as reported at the end of Q3 2013.